BPC
NTLA icon

Banque Pictet & Cie’s Intellia Therapeutics NTLA Stock Holding History

Banque Pictet & Cie’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,878
Closed -$592K – 570
2023
Q1 		$592K Sell
15,878
-7,199
-31% -$282K 0.01% 440
2022
Q4 		$805K Sell
23,077
-83,382
-78% -$3.96M 0.01% 428
2022
Q3 		$5.96M Buy
106,459
+24,282
+30% +$1.51M 0.06% 157
2022
Q2 		$4.25K Buy
82,177
+12,688
+18% +$644K 0.04% 193
2022
Q1 		$5.05M Buy
69,489
+8,874
+15% +$752K 0.04% 192
2021
Q4 		$7.17M Buy
+60,615
New +$7.59M 0.05% 174

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Banque Pictet & Cie's NTLA Position: Q2 2023 in Review

Banque Pictet & Cie sold out of Intellia Therapeutics (NTLA) in Q2 2023, closing a stake of 15,878 shares — an estimated $592K sold.

Banque Pictet & Cie first reported a position in NTLA in Q4 2021 and held it in 6 quarters. The position peaked at $7.17M in Q4 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2023.

  • Banque Pictet & Cie reported no remaining Intellia Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Banque Pictet & Cie sold 15,878 Intellia Therapeutics shares in Q2 2023, an estimated $592K.
  • Banque Pictet & Cie first reported a position in Intellia Therapeutics in Q4 2021 and held it in 6 quarters.
  • Banque Pictet & Cie's Intellia Therapeutics position peaked at $7.17M in Q4 2021.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2023.

Based on Banque Pictet & Cie's 13F filing for Q2 2023, filed 4 Aug 2023.